ABSTRACT
OBJETIVO: El presente estudio evalúa el valor pronóstico de los parámetros metabólicos relacionados con el tumor primario en el 18F-FDG PET/TC pretratamiento en pacientes con adenocarcinoma pulmonar en fase avanzada. MATERIALES Y MÉTODOS: Este estudio retrospectivo incluyó 258 pacientes con adenocarcinoma pulmonar en fase avanzada a los que se les realizó un escáner PET/TC del pretratamiento y para quienes estaba disponible el receptor del factor de crecimiento epidérmico (EGFR)/cinasa de linfoma anaplásico (ALK). Se registraron el valor máximo de captación estándar (SUVmáx), SUVmean, el volumen tumoral metabólico (MTV) y la glucólisis total de la lesión (TLG) relacionados con el tumor primario en la PET basal y diversos factores clínicos. Se evaluó la relación entre estos factores y la supervivencia global (OS) y la supervivencia libre de progresión (PFS). RESULTADOS: El estudio incluyó a 258 pacientes con adenocarcinoma pulmonar en fases IIIB-IV (72 mujeres, 186 hombres, de edad media 60,4 +/- 10,4 años), 210 de los cuales murieron y 243 progresaron en el momento del análisis. La OS y PFS media de los pacientes fue de 16 +/- 1,9 y 5 +/- 0,5 meses respectivamente. El presente estudio no reveló una relación significativa entre la OS o PFS y el sexo, el estatus de fumador, la presencia de metástasis a distancia, la edad y el tamaño del tumor. No hubo una diferencia significativa en la OS y PFS de los pacientes que dieron resultados negativos en mutaciones EGFR/reorganizaciones ALK y los que dieron resultados positivos para ambos o para las mutaciones EGFR o las reorganizaciones ALK. La OS fue significativamente más larga en pacientes con MTV bajo (p = 0,011) y en aquellos con TLG bajo (p = 0,012) que en los que los tenían altos. No obstante, no se encontró una relación significativa entre los valores SUVmáx y SUVmean y la OS, ni entre todos los parámetros del PET y la PFS. CONCLUSIÓN: Los MTV y TLG que reflejen la carga tumoral metabólica pueden predecir la OS en pacientes con adenocarcinoma pulmonar avanzado
OBJECTIVE: The present study evaluates the prognostic value of metabolic parameters related to the primary tumor on pretreatment 18F FDG PET/CT in patients with advanced stage lung adenocarcinoma. MATERIAL AND METHODS: This retrospective study included 258 patients with advanced stage lung adenocarcinoma who underwent pretreatment PET/CT scan, and for whom epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) status was available. The maximum standardized uptake value (SUVmax), SUVmean, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) related to the primary tumor at the baseline PET and various clinical factors were recorded. The relation between these factors and overall survival (OS) and progression-free survival (PFS) was evaluated. RESULTS: The study included 258 patients with stage IIIB-IV lung adenocarcinoma (72 female, 186 male, mean age 60.4+/-10.4 years), 210 of which died and 243 of which progressed at the time of analysis. The median OS and PFS of the patients were 16+/-1.9 and 5+/-0.5 months, respectively. The present study revealed no significant relation between OS or PFS and gender, smoking status, presence of distant metastasis, age and tumor size. There was no significant difference in the OS and PFS of patients testing negative for EGFR mutations/ALK rearrangements and those testing positive for both or either of the EGFR mutations and ALK rearrangements. OS was significantly longer in patients with low MTV(p = 0.011) and those with low TLG(p = 0.012) than high ones. However, no significant relation was found between SUVmax and SUVmean values and OS, and between all PET parameters and PFS. CONCLUSION: MTV and TLG reflecting the metabolic tumor burden can predict OS in patients with advanced lung adenocarcinoma
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Adenocarcinoma of Lung/diagnostic imaging , Adenocarcinoma of Lung/mortality , Fluorodeoxyglucose F18 , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/mortality , Tomography, X-Ray Computed/methods , Radiopharmaceuticals , Adenocarcinoma of Lung/metabolism , Adenocarcinoma of Lung/pathology , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/metabolism , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Disease Progression , ErbB Receptors/genetics , Fluorodeoxyglucose F18/pharmacokinetics , Genes, erbB , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Mutation , Positron-Emission Tomography , Prognosis , Radiopharmaceuticals/pharmacokinetics , Retrospective Studies , Sex Factors , Tumor BurdenABSTRACT
No disponible
Subject(s)
Humans , Male , Aged, 80 and over , Biomarkers, Tumor/therapeutic use , ErbB Receptors/genetics , Mutation , Adenocarcinoma of Lung/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Genes, erbB/genetics , Lung Neoplasms/diagnosis , Lung Neoplasms/genetics , Protein-Tyrosine Kinases/antagonists & inhibitors , Adenocarcinoma of Lung/diagnostic imaging , Tomography, X-Ray Computed/methods , Polymerase Chain Reaction/methodsABSTRACT
BACKGROUND: Epidermal growth factor receptor family members such as ErbB1 and ErbB3 are involved in tumor progression and metastasis. Although, there are various reports about the prognostic value of EGFR members separately in gastric cancer, there is not any report about the probable correlation between ErbB1 and ErbB3 co-expression and gastric cancer prognosis. In present study, we assessed the correlation between ErbB1 and ErbB3 co-overexpression (in the level of mRNA and protein expression) and gastric cancer prognosis for the first time. METHODS: ErbB1 and ErbB3 expressions were analyzed by immunohistochemistry and real-time PCR in 50 patients with gastric cancer. Parametric correlations were done between the ErbB1 and ErbB3 expression and clinicopathological features. Multivariate and logistic regression analyses were also done to assess the roles of ErbB1 and ErbB3 in tumor prognosis and survival. RESULTS: There were significant correlations between ErbB1/ErbB3 co-overexpression and tumor size (p = 0.026), macroscopic features (p < 0.05), tumor differentiation (p < 0.05), stage of tumor (p < 0.05), and recurrence (p < 0.05). Moreover, ErbB1/ErbB3 co-overexpression may predict the survival status of patients (p < 0.05). CONCLUSION: ErbB1 and ErbB3 co-overexpression is accompanied with the poor prognosis and can be used efficiently in targeted therapy of gastric cancer patients.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Stomach Neoplasms/metabolism , Biomarkers, Tumor/metabolism , Genes, erbB-1 , Receptor, ErbB-3/metabolism , Prognosis , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Immunohistochemistry , Gene Expression Regulation, Neoplastic , Survival Rate , Genes, erbB , Receptor, ErbB-3/genetics , Real-Time Polymerase Chain ReactionABSTRACT
No disponible
Subject(s)
Humans , Genomics/trends , Breast Neoplasms/genetics , Transcriptome/genetics , Genes, erbB-2/genetics , Genes, erbB/genetics , Proteomics/trendsABSTRACT
The authors (Garcia Carrancá A, Zentero Galindo E, Jiménez Farfán MD and Hernandez Guerrero JC) express that one of the figures of the original article (Jacinto-Alemán LF, García-Carrancá A, Leyba Huerta ER, Zenteno-Galindo E, Jiménez-Farfán MD, Hernández-Guerrero JC. erbB expression changes in ethanol and 7,12- dimethylbenz (a)anthracene-induced oral carcinogenesis. Med Oral Patol Oral Cir Bucal. 2013 Mar 1;18(2):e325-31.) corresponding to Western blots have not been found and the voluntary alteration of this figure is evident. The coauthors Alejandro García Carranca, Edgar Zenteno Galindo, Maria Dolores Jiménez Farfán and Juan Carlos Hernández Guerrero have made the decision to take back what has been published, as they have come to the conclusion, that at least this result is false.The editor declare that the journal had the signed copyright by the authors when the arti-cle was initially published. This copyright document certifies that the undersigned authors war-rants that the article is original; is not under consideration by another publication; and its tables or figures have not been previously published. The authors confirmed that the final ar-ticle had been read and each author ́s contribution had been approved by the appropriate author. The editor has made the decision to retract the article due to the above comments of some authors against the rest. The editors apologize to the readers and reviewers of Med Oral Patol Oral Cir Bucal for the incon-venience caused by the authors of the article
No disponible
Subject(s)
Genes, erbB , Ethanol , Benz(a)AnthracenesABSTRACT
Objetive: The aim of this study was to determine erbB expression in normal mucosa, oral dysplasia, and invasive carcinomas developed in the hamsters buccal pouch chemical carcinogenesis model. Study design: Fifty Syrian golden hamsters were equally divided in five groups (A-E); two controls and three experimental group exposed to alcohol, DMBA, or both for 14 weeks. Number of tumors per cheek, volume, histological condition, erbB expression were determined and results were analyzed by the MannWhitney U and Dunns test. Results: Control groups and those exposed to alcohol (A, B and C respectively) only presented clinical and histological normal mucosa; while those exposed to DMBA or DMBA plus alcohol (D and E groups) developed dysplasia and invasive carcinomas. erbB2, erbB3, and erbB4 increased their expression in alcohol-exposed mucosa, dysplasia, and invasive carcinomas. We observed a similar expression level for erbB2 in dysplasia and carcinomas; while, erbB3 and erbB4 were similar only in carcinomas. Conclusion: The DMBA and alcohol can be considered as carcinogen and promoter for oral carcinogenesis. TheerbB expression is different according to their histological condition, suggesting differential participation of theerbB family in oral carcinogenesis induced by alcohol and DMBA (AU)
Subject(s)
Humans , Genes, erbB/genetics , Carcinogenicity Tests/methods , Neoplasms/genetics , Ethanol/analysis , 9,10-Dimethyl-1,2-benzanthracene/analysis , Neoplasms, Squamous Cell/pathology , Odontogenic Tumor, Squamous/pathologyABSTRACT
No disponible
Subject(s)
Animals , Female , Dogs , Mammary Neoplasms, Animal/immunology , Immunohistochemistry/methods , Tumor Suppressor Protein p53/immunology , Genes, erbB/immunology , Ki-67 Antigen/immunologyABSTRACT
No disponible
Subject(s)
Humans , Female , Breast Neoplasms/pathology , Neoplasms, Hormone-Dependent/pathology , Receptors, Estrogen/analysis , Growth Substances/analysis , Epidermal Growth Factor/analysis , Genes, erbB , Somatomedins/analysis , Prostaglandin-Endoperoxide Synthases , Proto-Oncogene Proteins c-kit/analysisABSTRACT
Objetive: ErbB Receptor Tyrosine Kinases possess an establishedrole in mammary gland development and breast tumorigenesis.We aimed to assess the expression of c-erbB3and c-erbB4 RTKs in early breast carcinomas and investigateits possible correlation with Estrogen or Progesterone Receptors,tumor stage and grade, disease recurrence and patientsoutcome.Patients and methods: Forty-nine specimens of earlybreast carcinomas deriving from patients that had sustainedpartial or total mastectomy with axillary lymph node resectionwere studied retrospectively. Expression of RTKs was detectedimplementing: a) an anti-HER-3 mouse polyclonal antibody;and b) an anti-HER-4 mouse polyclonal antibody. For both cerbB3and c-erbB4, either a cytoplasmic or a nuclear stainingpattern of tumor cells was considered positive.Results: Expression of c-erbB4 exhibited statistically significantassociation with tumor grade and unfavorable patientsoutcome. C-erbB3 expression did not correlate with tumorrecurrence or patients outcome.No association was established between the expression ofboth RTKs and that of Estrogen or Progesterone Receptors.C-erbB4 expression did not posess statistically significant associationwith patients death or disease recurrence. C-erbB3 expressiondid not correlate with tumor grade or recurrence andpatients death.Conclusions: In the context of compound molecularmechanisms, alterations in c-erbB3 and c-erbB4 expressionmerit appraisal as future interventions in breast cancer treatmen (AU)
No disponible
Subject(s)
Humans , Female , Breast Neoplasms/pathology , Oncogene Proteins v-erbB/analysis , Mastectomy , Genes, erbB/genetics , Immunohistochemistry/methods , Disease-Free Survival , Disease ProgressionABSTRACT
Carcinoma de células transicionais (CCT) é o tipo histológico predominante de tumor epitelial maligno da bexiga. Estudos genéticos sobre os processos de iniciação e de progressão tumoral têm contribuído para o melhor entendimento dos mecanismos de carcinogênese urotelial. A ocorrência de alterações genéticas, principalmente em genes supressores de tumor e oncogenes, como CDKN-2, ARF, RB, TP53, H-RAS, BCL-2, c_ERBB-2, cyclin D1 e o receptor EGF-R, tem sido relatada em CCT. A progressão desses tumores parece ocorrer conjuntamente com a aquisição de anomalias cromossômicas com deleções em 9p, 9q e 17p e ganhos em 1q, 5p, 7p, 11q e 17q. Assim, a avaliação genética utilizando marcadores genéticos para o diagnóstico precoce e risco de recorrência e metástases torna-se um método promissor